A technical note on emerging combination approach involved in the onconanotherapeutics

Mohammad Kashif Iqubal\textsuperscript{a,b}, Harsimran Kaur\textsuperscript{c}, Shadab Md\textsuperscript{d}, Nabil A. Alhakamy\textsuperscript{d}, Ashif Iqubal\textsuperscript{e}, Javed Ali\textsuperscript{b} and Sanjula Baboota\textsuperscript{b}

\textsuperscript{a}Product Development Department, Sentiss Research Centre, Sentiss Pharma Pvt Ltd, Gurugram, India; \textsuperscript{b}Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India; \textsuperscript{c}Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; \textsuperscript{d}Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India

ABSTRACT
Cancer is the second cause of mortality worldwide, and the currently available conventional treatment approach is associated with serious side effects and poor clinical outcomes. Based on the outcome of the exploratory preclinical and clinical studies, it was found that therapeutic response increases multiple folds when anticancer drugs are used in combination. However, the conventional combination of anticancer drugs was associated with various limitations such as increased cost of treatment, systemic toxicity, drug resistance, and reduced pharmacokinetic attributes. Hence, attempts were made to formulate nanocarrier fabricated combinatorial drugs (NFCDs) to effectively manage and treat cancer. This approach offers several advantages, such as improved stability, lower drug exposure, targeted drug delivery, low side effects, and improved clinical outcome. Hence, in this review, first time, we have discussed the recent advancement and various types of nano carrier-based combinatorial drug delivery systems in a different type of cancer and highlighted the personalized combinatorial theranostic medicine as a futuristic anticancer treatment approach.

ARTICLE HISTORY
Received 13 July 2022
Revised 6 September 2022
Accepted 12 September 2022

KEYWORDS
Chemotherapy; nanotechnology; dual-drug combination; immunotherapy; personalized medicine

1. Introduction
Cancer is one of the leading causes of mortality and morbidity worldwide. More than 10 million deaths have been recorded due to different types of cancer. Lung cancer (18%), followed by a colon (9.4%) and liver (8.3%), is the leading cause of death. Considering the incidence of cancer, breast cancer ranks first (11.7%), followed by the lung (11.4%), and colon (10%). Moreover, as per the WHO report, in China, a maximum number of deaths have been reported, followed by India and the USA, whereas the incidence of cancer is highest in China, followed by the USA and India, as shown in Figure 1 (Siegel et al., 2022). Considering the etiology of cancer, it is multifactorial in origin but begins from the alteration in DNA. No doubt, mutations are primarily responsible for various types of cancer. Still, apart from the role of mutation and mutagens, various other oncogenic factors such as radiation, chemical exposures, stress, exposure of drugs, etc., are also equally responsible (Maiorino et al., 2022). Recent studies have shown that epigenetic pathways that regulate the expression of various genes also play a pivotal role in the event of carcinogenesis. Studies have further shown abnormal methylation, such as hypo or hypermethylation, and histone deacetylase activity in the carcinogenesis pathogenesis (Fardi et al., 2018). Hence, the cumulative effect of mutational factors and abnormal epigenetic mechanisms is responsible for the emergence of the malignant phenotype ‘malignant transformation’. Moreover, based on the exploratory studies, it was found that multiple pathways are accountable for the transformation of a normal cell into a malignant cell. No doubt, tumorigenesis begins clonally with a single cell and undergoes a neoplastic transformation. Hence, the identification of the clonal cells is a pivotal indicator for the initiation of tumorigenesis (Nichenametla et al., 2006).

It is also important to understand that in response to persistent injury, normal tissue responds by the loss of proliferation mechanism, which indeed is regulated by the specific receptors, signaling molecules, enzymes, and other biochemical machinery (Tuli et al., 2021). In normal physiological conditions, the proliferative process is a highly controlled and regulated process that retains the homeostatic functions. In contrast, uncontrolled proliferation occurs during carcinogenesis, leading to tumor initiation, progression, invasion, and metastasis (Iqubal et al., 2021b). Moreover, in the event of tumorigenesis, oncogenes play a pivotal role. These oncogenes have been divided into five categories: growth factors, their receptors,
signal transducers, transcription factors, and various cyclins (Croce, 2008). Some commonly identified growth factors and their receptors are vascular endothelial growth factor-receptor (VEGF/VEGF-R), epidermal growth factor-receptor (EGF/EGFR), Erb B, etc., whereas some of the commonly identified pronocogenic intracellular signal transducers are rapidly accelerated fibrosarcoma (RAF), rat sarcoma virus (RAS), etc. Transcription factors involved in oncogenesis primarily regulate gene expression via binding to the specific site of DNA. MYC, JUN, and FOS are some of the commonly studied transcriptional factors. Cyclins, on the other hand, are proteins that modulate the cell cycle. These cyclins play their role at specific checkpoints of cell cycles, interacting with various enzymes known as cyclin-dependent kinases (CDKs) and enabling the progression of the cell cycle. Exploratory studies have found various CDKs, such as cyclin D1 and get dysregulated and participate in the event of tumorigenesis (Iqubal et al., 2020).

It is further important to understand that structural alteration in genes also transforms them into oncogenes. The structural damage mainly occurs because of mutation of nucleotides or due to chromosomal translational events manifested by the chemicals or radiation (Jones & Baylin, 2007). The best example can be seen in the case of RAS proteins that exist in three forms, K-RAS, N-RAS, and H-RAS and act as a GTPase that regulates the phosphorylation of GTP, leading to cell proliferation and cell survival. In the case of their mutation, Ras members bind to the receptors of growth factors, undergoes dimerization, autophosphorylation and conformational changes leading to uncontrolled cell division and survival of tumor cells (Porter et al., 2016).

Doubtless, tumor cell survival is a major clinical concern for clinicians, but at the same time, angiogenesis and metastasis is another important concern that considerably affects the clinical outcomes. Vascularization is important for the growth of tumor cells, and here the role of VEGF and FGF is decisive (Kawada & Taketo, 2011). Apart from the role of growth factors, matrix metalloproteinases (MMPs), collagens nuclear factor kappa B (NF-kB), and other cytokines also play a pathological role in the event of angiogenesis and hence the progression of tumor cells. During the course of angiogenesis, continuous leakage of macromolecules and deposition of fibrins act as a tool for tumor stroma formation and their migration that eventually leads to tumor metastasis (Iqubal et al., 2020).

Henceforth, it can be concluded that the incidence and prevalence of cancers are increasing exponentially and affect the lives of patients considerably. No doubt, with the time and advancement in the cellular and molecular techniques, detailed cellular and sub-cellular pathology of cancer have been explored and various newer drugs have been developed (Iqubal et al., 2020). Despite numerous advancements in treatment modality using chemotherapy, radiotherapy, surgical intervention, and immunotherapy, cancer patients’ survival rate and quality of life have not improved considerably (Ayoub, 2021). Thus, attempts were made to use a combination of chemotherapy and immunotherapy to improve the quality of life of chemotherapeutically treated patients (Al-Lazikani et al., 2012). Hence, in the present review, we first discussed the combinational therapy of conventional drugs, their limitations, and the pharmacotherapeutic role of various onconanotherapeutics used in various types of cancers.

2. Oncotherapeutics for the management and treatment of cancer

The concept of combination therapy was first implemented by Emil et al., in 1965 in one of a pediatric patient diagnosed with acute leukemia, and the outcome was successful (Frei et al., 1965). After the success of this combination therapy, the entire journey of treatment and management of changed considerably. More and more emphasis were put on the
rationale exploration of various combination therapy with the aim of targeting multiple pathways to generate favorable clinical outcome (Ismail et al., 2020). In this journey, genomics, oncogenomics, proteomics, and transcriptomics played a significant role in the identification of various molecular targets for the combinational anticancer drugs (Falzone et al., 2018). Based on the published evidence and our previous work, we concluded that the combinational therapeutic approach offers several benefits over single therapy (Md et al., 2020). Firstly, combinational therapy significantly improves the clinical outcome, exhibit superior therapeutic effect as compared to the single drugs. Combinational drugs effectively overcome the clonal heterogeneity, and reduced the toxicity as a comparatively lower amount of drug is used. Moreover, combinational therapy significantly reduces drug resistance and increases patients’ survival rate (Ayoub, 2021).

No doubt, combinational therapy offers several advantages over single drug therapy, but still concern exists. One of the major issues with this approach is drug–drug interaction and unpredictable pharmacokinetic profile that eventually influence the desired clinical outcome. Additionally, when a lower amount of drug is used to avoid toxicity, sometime results in a suboptimal therapeutic response and also the predicted synergistic effect is inconclusive (Chou, 2010). It is further important to bring in notice that most of the combinational drug used among the cancer patients were primarily based on the empirical clinical experimental settings and unfortunately, the mechanistic approach and the rationale for the combination was lacking (Palmer et al., 2019). Thus, to overcome these issues, Narayan et al. have used the typical approach known as the ‘drug atlas’, where novel and rationale drug combinations with their synergistic effects were explored. In the approach of ‘drug atlas’ specific pathways and processes were identified against which tumor cells can be attacked and killed by combination of drugs (Narayan et al., 2020). ‘Restrictive combination’ is another approach where a clear difference is observed between cancerous and normal cells upon application of dual drugs (Blagosklonny, 2008). More recently, Tolcher et al. have designed and developed ‘CombiPlex’ technology where the probability of possible anticancer activity and a synergistic effect was evaluated (Tolcher & Mayer, 2018).

Colombo et al. have evaluated the anticancer effect of birinapant (apoptosis inhibitor) and ralimetinib (p38 inhibitor) in the liver kinase B1 deleted clone and RAS mutated cell lines and the outcome showed restoration of kinase activity (Colombo et al., 2020). In another study by Mortensen et al., the combination of onalespib and cisplatin significantly increased the antiproliferative, pro apoptotic, and antimigratory effect (Mortensen et al., 2020). In one of the interesting findings, Shi et al. showed that when regorafenib and ABC294640 (SphK2 inhibitor) were used in liver cancer, regorafenib resistance was significantly reduced and marked improvement in the anticancer effect was observed, as compared to the individual drugs (Shi et al., 2020). Drug resistance is one of the major concerns for the oncologist world-wide, and the use of a single drug is extensively reported to exhibit drug resistance (Bukowska et al., 2015). Studies have shown that overexpressed ATP-binding cassette (ABC) efflux transporters are associated with resistance and considering this, Yang et al. have explored the effect of sitrafatinib (a tyrosine kinase inhibitor) as a blocker of ABC efflux transported and exhibited a significant anticancer effect (Bukowska et al., 2015; Ju Yang et al., 2016).

Drug repurposing is among the emerging approaches for the use of already FDA-approved drugs for the treatment and management of various types of cancer. In one of the interesting studies, Hsu et al. explored the synergistic effect of sildenafil (phosphodiesterase inhibitor) and vincristine (calcium channel blocker) against castration-resistant prostate cancer (CRPC). The outcome of the study showed that sildenafil exhibited a synergistic effect with vincristine and induced cell cycle arrest (Hsu et al., 2020). Hence, the use of combination therapy in the treatment and management of cancer has become standard practice. Henceforth, many FDA-approved drugs and their combinations are routinely used. Despite, this targeted mechanism of action, low solubility, low bioavailability and reduced therapeutic outcome are major limitations (Table 1).

3. Onconanotherapeutics

Nanotechnology has been progressively utilized since the past few years for therapeutic purposes, including applications for diagnosis, treatment, and tumor targeting in a safe and efficacious manner. The nanocarriers used for therapeutic benefits account for specific sizes, shapes, and surficial properties owing to their influence on nanocarrier-based drug delivery efficiency and accordingly provide improved therapeutic value. With reference to the size, nanocarriers within diametric sizes ranging from 10 to 100 nm are generally characterized as suitable candidates for cancer therapeutics because they can deliver drugs effectively along with achieving enhanced permeability and retention (EPR) effect. Nanocarrier-based drug delivery systems have exhibited propitious merits in cancer treatment, namely good pharmacokinetics, precise targeting of tumor cells, reduced incidence of side effects, and drug resistance (Dadwal et al., 2018; Palazzolo et al., 2018). Nanocarriers in cancer management are usually selected based on their characteristics and the pathophysiology of the tumors. Several types of nanocarriers, such as protein-based nanoparticles (NPs), silica-based nanocarriers, liposomes, solid lipid nanocarriers, etc., have been developed (Yoon et al., 2020), and their brief classification is presented in Figure 2. Mechanically, the anti-carcinogenic effect of nanocarriers involves targeting malignant cells through their carrier effect and the positioning impact of the targeting moiety after being absorbed, followed by the release of drugs into malignant cells, as a measure to induce cell death. The drugs entrapped within the nanocarriers include traditional chemotherapeutic agents and nucleic acids, indicating that they can play a crucial part in both gene therapy and chemotherapy. In the bargain, nanocarriers offer a platform for some poorly soluble drugs, which can aid in their encapsulation and deliver the drugs into the circulatory environment (Yao et al., 2020). As a consequence of the size, surface properties, and function of nanocarriers in enhancing permeability and retention, it can increase the
half-life of drugs and improve their availability in malignant cells (Gavas et al., 2021; Kalyane et al., 2019). In the interim, the targeting approach shields normal cells from the unwanted effects of drug molecules and helps alleviate the adverse effects of anticancer therapy. For example, DOX-loaded polyethylene glycol (PEG) or PEGylated liposomes impart reduced cardiotoxicity in comparison to free DOX (O’Brien et al., 2004). Furthermore, various studies have shown the application of nanocarriers in immunotherapy for cancer (Riley & Day, 2017; Yoon et al., 2018), and this approach of the delivery system is executed with the belief of enhancing immunotherapy besides reversing the tumor immunosuppressive microenvironment (Yao et al., 2020).

In the late years, a rising number of nanocarrier-based drug delivery systems have been commercialized or entered the stage of clinical trials. The phase I clinical trial that utilized a targeted NP-based system to deliver small interfering RNA (siRNA) in patients with solid tumors was conducted in 2010 (Davis et al., 2010). Another clinical study revealed a promising tumor treatment competency of actively targeted polymeric NPs containing the chemotherapeutic docetaxel in comparison to a solvent-based docetaxel formulation (Hrkach et al., 2012). The formulation of hybrid nanocarriers has paved the way in the area of nanocarrier-based drug delivery systems. Hybrid nanocarriers offer combined benefits of different nanocarriers; as a result, enhancing the stability and functionality of every delivery system (Yao et al., 2020).

Over and above, nanocarriers have unveiled certain advantages with respect to antitumor multidrug resistance (MDR), as a consequence of offering a podium for combination drug therapy as well as hindering the biz of some mechanisms of drug resistance, like efflux transporters on cell membranes (W. Li et al., 2016). Presently, nanocarrier-based therapy has been reported to have prospects of overcoming MDR in

| Drug 1 | Drug 2 | Type of cancer |
|--------|--------|----------------|
| Ipilimumab | Nivolumab | Advanced kidney cancer |
| Nivolumab | Ipilimumab | Advanced colorectal cancer |
| Cisplatin | Navelbine | Non-small-cell lung cancer (NSCLC) |
| Doxorubicin (DOX) | Cyclophosphamide | Breast cancer |
| DOX, vinblastine | Bleomycin, dacarbazine | Breast cancer |
| S-FU | Axitinib | Breast cancer |
| S-FU | Alpelisib | Breast cancer |
| S-FU | Afatinib | Colon cancer |
| S-FU | Crizotinib | Pancreatic cancer |
| Carfilzomib | Daratumumab, dexamethasone | Refractory multiple myeloma |
| Daratumumab | Hyaluronidase-fhj | Relapsed/refractory multiple myeloma |
| Atezolizumab | Cobimetinib and vemurafenib | Metastatic melanoma |
| Atezolizumab | Bevacizumab | Unresectable or metastatic hepatocellular carcinoma |
| Decitabine | Cedazuridine | Myelodysplastic syndrome |
| Pertuzumab | Trastuzumab, and hyaluronidase | Multiple myeloma |
| Tucatinib | Trastuzumab and capcitabine | Her2-positive breast cancer |
| Neratinib | Capcitabine | Her2-positive breast cancer |
| Ramucirumab | Erlotinib | Metastatic NSCLC |
| Olaparib | Bevacizumab | Advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer |
| Ibrutinib | Rituximab | Chronic lymphocytic leukemia |
| Encorafenib | Cetuximab | Metastatic colorectal cancer |
| Durvalumab | Etoposide | Small cell lung cancer |
| Isatuximab-irfc | Pomalidomide and dexamethasone | Multiple myeloma |

5-Fu: 5-Florouracil; DOX: Doxorubicin.
several types of cancers, including prostate cancer (J. Zhang et al., 2019), ovarian cancer (H. Wang et al., 2018), and breast cancer (Alimoradi et al., 2018). Ergo, nanocarriers in the field of medicine have laid the foundations for cancer treatment, and combining these two fields demands more in-depth research.

4. Combination based onconanotherapeutics

As evident from numerous published evidences, various attempts were made by the researchers to manage and treat cancers. Among various treatment modalities, chemotherapy has remained the primary pharmacotherapeutic approach, but instead of many advances, there exists multiple for this approach (Papac, 2010). Previously and also currently, in general, single anticancer drugs were used that specifically target the single cancer signaling pathways. This approach was found to be positively correlated with the drug resistance, side effects, and altered pharmacokinetic attributes (Goodman & Wintrobe, 1946). Hence, attempts were made to use a combination of two or more drug, but again, a major issue of the unpredicted pharmacokinetic and pharmacodynamic profile due to the difference in dosing time were found (Kent & Huber, 1999). Hence, to overcome this issue, a combination based nanotechnological approach was used where different types of nanocarriers were used for the safe and effective drug delivery (Fellmann et al., 2017). A significant advantage of using combination based nanocarrier is the encapsulation of multiple drugs with an increased load capacity that effectively deliver the drug at the targeted site at a pre-determined rate. Another advantage of using nanocarriers for combinational drug delivery is the use of a lower drug dose that results in better safety profile and the possibility of avoiding drug resistance.

Moreover, the use of a nanocarrier for the dual drug delivery also helps in bypassing the drug uptake via endocytosis and exhibits superior bioavailability (Yasmeen et al., 2021). In conclusion, the nanoformulated combinatorial drugs (NFCDs) delivery system offers several advantages, such as synergistic effect, minimal drug resistance, controlled drug release, and superior anticancer effect with an improved safety profile as shown in Figure 3.

4.1. Colorectal cancer

A recent study involved the combined efficacy of two anticancer drugs, namely SN38 (an active form of irinotecan) and salinomycin (Sal), an ionophore, by encapsulating them into lipid nanocapsules (LNC). The selective combination was proposed to reduce the systemic toxicity and enhance the stability. The clonogenicity assay performed on HCT116 cell lines revealed the IC_{50} values for SN38 as 0.5 ng/ml and for Sal as 2.4 µg/ml. Activation of GLS2 (essential ferroptosis activator), MT1 gene and upregulation of CHAC1 and PTGS2 (prototypic markers of ferroptosis) was observed, as a result of ferroptosis activation, mediated by Sal, which confirmed its anticarcinogenic effect. The combined and simultaneous treatment of both the drugs along with the IC_{50} concentrations exhibits a synergistic effect at combination index (CI) < 0. The resultant formulation, i.e., the LNC were in the size range of 50 nm. The combined drugs showed a great efficiency to target CRCs in 3D structures, independent of cell heterogeneity and plasticity. The overall results proved that SN38 and Sal together are a promising solution for treating CRCs (Tsakiris et al., 2020).

In another experiment, emulsomes were synthesized by incorporating curcumin and piperine to achieve a synergistic anticarcinogenic effect. The average diameter of curcumin loaded emulsomes was observed to be 184.21 nm, whereas...
piperine linked emulsomes had a larger average size of 248.76 nm. When administered individually, piperine both in its free and emulsome forms did not exhibit any remarkable change on HCT116 cell viability, in vitro but as an adjuvant it showed a significant enhancement in curcumin’s action. Piperine and curcumin-loaded emulsomes, combined in concentrations of 7 µm and 25 µm, respectively, acted as a suitable therapy for inducing cancer cell death. G2/M arrest in the HCT116 cell line and induction of apoptotic response further confirmed the anticancer properties of the compounds selected. A four-fold increase in caspase 3 level was obtained with curcumin-emulsomes while a six-fold increase was reported with piperine-emulsomes. Hence, the overall studies indicate the antitumor activity of the compounds which proves them as a suitable approach for further in vivo studies (Bolat et al., 2020).

In one of the studies, PEG-linked poly(caprolactone) block copolymer (PCL) was utilized for the co-loading of 5-FU and plasmid encoding EGFP. The average hydrodynamic size of empty nanocarriers and 5-FU-loaded nanocarriers was reported to be around 110 nm, whereas the DNA-trapped DNA-loaded nanocarriers and DNA and 5-FU co-loaded nanocarriers showed size of about 145 nm. The PDI was found to be below 0.2. The drug and gene entrapment efficiency of 5-FU was observed to be around 80% and 90%, respectively. A dose-dependent cytotoxicity was seen in the 5-FU containing groups. The inhibition capacity in colon cancer cells was stronger with 5-FU-loaded nanocarriers as opposed to free 5-FU. The tumor volume of 5-FU-loaded nanocarriers and DNA and 5-FU co-loaded nanocarriers was significantly reduced, which resulted in the suppression of tumor growth. The drug and gene co-loaded nanocarriers exhibited antitumor properties to a better extent and efficient gene delivery was attained at the target site (Z. Wang et al., 2018).

Chimeric antigen receptor modified T cells are a new class of candidates for the treatment of carcinoma. Zhang et al. utilized these anticancer agents in a treatment model for colorectal cancer. The study involved the formation of chimeric antigen receptor (CAR)belonging to second-generation, targeting epithelial cell adhesion molecule and a combined approach of CAR specific natural killer (NK) cells along with regorafenib was employed to exploit their synergistic potential. The escalating response in the in vitro release profile of cytokines in NK-92 cell lines linked to CAR, is attributed to the recognition ability and activation mechanism mediated by EpCAM, i.e., positive colon cancer cells. A remarkable reduction in the HCT-8 tumor growth was observed by the co-administration of regorafenib and CAR associated NK-92 cells, in contrast to the dose of plain moieties. This further highlights the synergistic anticarcinogenic capacity of the combination to target CRCs (Q. Zhang et al., 2019).

### 4.2. Skin cancer

Dacarbazine, known as a DNA alkylating agent, possesses potent chemotherapeutic activity. However, associated with limitations such as short half-life and poor aqueous solubility, it offers reduced efficacy. To overcome these barriers, Li and Han selected all-trans-retinoic acid, an anticarcinogenic compound to promote co-delivery along with dacarbazine that would result in a synergistic effect as compared with the individual compound. The research was conducted to target melanoma malignancies by formulating a combination of dacarbazine and all trans-retinoic acid-loaded lipid nanof ormulations, thereby resulting in enhanced antitumor efficacy, attributed to the synergistic action. The particle size of nanof ormulation was reported to be 121.5 ± 1.65 nm with zeta potential of -23.5 ± 0.85 mV and PDI of 0.134. The particle size of optimized formulation was 138.2 ± 1.28 nm with zeta potential of -25.4 ± 0.58 mV and PDI of 0.159. Liposomal car -riers exhibited significant anticarcinogenic toward the mela -noma cancer cell death. In addition, inhibition of cell cycle progression and greater apoptosis mechanism was seen in the B16F10 cells after treatment with the selected formulation, which indicates excellent antitumor efficacy of the combinational approach. The results prove that the lipid complex suppresses melanoma cell proliferation, induces significant apoptosis and restricts cell cycle progression and migrations, which concludes it as a suitable candidate for melanoma malignancies (Li & Han, 2020).

To overcome the hindrance associated with dermal penetration of therapeutic candidates, nanoencapsulated dabrafenib (Db) and trametinib (Tb) were formulated using silica NPs linked to phthalocyanine (Pc), as a measure to prolong the circulation time and induce synergistic benefits via co-delivery approach. Anthracenediylbis(methylene)dimalonic acid (ABDA) was introduced as a trapping agent which differentiated the quenching efficiency of different formulations, suggesting that the amount of phthalocyanine and tetramethyl orthosilicate (TMOS) had a great significance in inducing appropriate response. The PDI, diametric size, and zeta potential figures were reported to be between 0.157 to 0.165, 29 to 39 nm and -20.5 to -22.1 mV, respectively. The administration of formulation in addition to the photodynamic therapy, exhibited a major apoptotic response, as evident from the intensified red fluorescence. The killing efficiency was more prominent with the combined treatment rather than single moieties. Thus, from the findings, it can be concluded that Db-Tb-Pc loaded silica NP contribute to the therapeutic regimen in synergy with photodynamic treatment (PDT) treatment (Tham et al., 2018).

Long et al. reported the combined effect of photothermal (PTT) and PDT, to destruct the tumor microenvironment while potentiating drug release from manganese dioxide and indocyanine green loaded derivative, incorporated in to the surface of bovine serum albumin (BSA) molecules for exploiting the anticarcinogenic properties. The fluorescence pattern of optimized nanocomplex was further studied using singlet oxygen sensor green (SOSG) medium, which resulted in generation of singlet oxygen species as an indicator of promising photodynamic effect. The cell destruction ability was confirmed at higher dose of formulation adjuvant to PTT and PDT therapies. The responses calculated depicted a huge difference in the cell death. Responses to the laser radiations can be related to the elevation in temperature and production of singlet oxygen. An impressive tumor inhibition was seen after subjecting mice to IV administration of the
formulation along with laser treatment, which highlights the proliferative action of nanoconjugate prepared (Wen et al., 2020).

In another study, celecoxib and plumbagin were combined together to formulate nano liposomes conjugate, which provided synergistic action to induce cell death. The mechanisms included inhibition of cyclooxygenase-2 (COX-2) and signal transducer and activator of transcription 3 (STAT3) pathway, which are the key targets in melanoma. The combined cytotoxic potential was confirmed by the Cl values that were below 0.9 at 10:1 ratio of Cele and Plumb. The normal cells did not exhibit any cytotoxic response while the melanoma cells underwent apoptosis with the dual-drug complex. Celeplum-777 induced a decline in cellular growth (62% in aqueous medium and 72% in saline base). The complementary enhancement in protein expression leads to successful inhibition in COX-2 pathway. Also reduced cyclin levels in melanoma and UACC 903 cell lines, restricted the proliferative mechanism and cell-arrest events. In nutshell, the unique model contributed to suppress tumor growth, thereby targeting crucial markers responsible for cell survival (Gowda et al., 2017).

PDT offers advantages in the field of skin ailments. Using this approach, the study by Nasr et al. involved comparison of the delivery profiles of ethosomal-chlorophyll derivative complex and chitosan nanocompounds loaded with layer of lipids, further linked to ferrous chlorophyll moieties. The skin retention capacity was reported to be 28% for lipidic chitosan conjugate, whereas 9% retention was observed for nanocarriers of ferrous derivative of chlorophyll in 24 hours time period. The optimized formulations administered to squamous cells were successful in inducing a declined response in the viable cells in synergy with the PDT, whereas no comparable difference was seen in the absence of laser therapy. The destruction of the membranous periphery of A431 spheroids subjected to lipidic carrier was a distinct feature to that of ethosomal conjugate, that caused insignificant effects to the tumor layer. Additionally, an escalating cytotoxic mechanism was observed in the group treated with lipid NPs, in contrast to the ethosome treated. Both nanoformulations acted in a synergistic way with PDT that paves a preferential selection to squamous cell carcinoma therapy (Nasr et al., 2019).

In another study, Iqubal et al. reported a synergistic effect of 5-FU when given with resveratrol via nanostructured lipid carrier (NLC) against skin cancer. In this study, the first optimized combinatorial NLC of 5-FU and resveratrol was selected, which had a particle size of 178.97 ± 2.54 nm and applied topically on diseased area. The therapeutic efficacy of NLC was evaluated by both in vitro and in vivo studies through estimation of histopathology, ultrastructural analysis, histomammography, etc., which exhibited significant (p < .05) result for nanoformulation as compared to conventional formulation (Iqubal et al., 2021a, 2021b).

4.3. Breast cancer

To improve the poor therapeutic effectiveness due to the limited bioavailability and low water solubility of paclitaxel (PTX), it was nanoformulated with dexamethasone (DEX). Hence, the study investigated the chemosensitizing role of combined treatment of PTX loaded PLGA NPs with DEX. Cellular proliferation was inhibited by PTX-NPs with IC\textsubscript{50} value reported as 6.67 μg/ml. The results revealed that MCF-7 cells showed decreased survival rate which confirms induction of dose dependent decrease in cell viability due to action of PTX. PTX-NPs showed a three-fold decrease in the IC\textsubscript{50} value. Major apoptotic section in MCF-7 cells was observed by PTX or PTX-NPs. The co-treatment of DEX/PTX in breast cancer cells exhibited the carcinogenic potential of the nanoformulated PTX (Diab et al., 2020).

Doxorubicin (DOX), mostly preferred chemotherapeutic agent is used for treating breast cancer. Despite its antitumor and cytotoxic potential, there are certain factors which limit its therapeutic efficacy. Hence, to overcome this difficulty, DOX is combined with siRNA nanodrug, which is responsible for inhibiting the antiapoptotic gene birc5/survivin. In a study performed by Ghosh et al., a therapeutic combination was applied to arrest tumor growth, which involved low-dose DOX and an antisurvivin siRNA nanodrug (MN-siBIRC5). The effect was examined in murine xenograft models of breast (triple negative) cancer. In vitro cell proliferation assay in breast cancer cell line BT-20 was carried out which revealed that DOX showed successful inhibition in cell proliferation at an IC\textsubscript{50} value below 0.7 μm. After the cells received treatment with DOX in addition to MN-siBIRC5, an apoptotic reaction was observed while the reverse sequential combination abrogated the benefit of the selected drug combination, which indicates that sequence is an important factor that can result in maximum tumor growth inhibition (Ghosh et al., 2014).

Certain cytotoxic drugs pose variable obstructions in the treatment pathway of cancer, which include less bioavailability and toxic events. Ding and the group worked on research that involved triple therapies as a treatment regimen for breast cancer, consisting of a combination of DOX, PTX and siRNA-based survivin, collectively loaded into the NP matrix. The combined anticancerous drugs were employed for their synergistic efficacy via triple mechanisms. A photothermal candidate, termed as PDA was projected onto the surface of nanocarrier-DPS complex. The results for photothermal studies of optimized formulation revealed a remarkable destruction of cancerous cells, with increase in temperature and higher loading of polymer linked to dopamine, which highlights the reason that photothermal efficiency is directly dependent on the amount of polymer dopamine conjugate. The antitumor potential explored by triple mechanism reported a rising proportion of cells being destroyed by the applied therapy, which is attributed to the synergistic response of chemical, photothermal, and gene delivery. The capability of such targeted nanocomposites in effectively producing a chemosensitive property suggests a promising treatment option for triple negative breast cancer (Ding et al., 2017).

The escalating issues offered by drug resistance that happen due to hyper expression of P-glycoprotein, occurs in a major proportion of breast cancer. To mitigate this difficulty, an appropriate strategy to regulate the over-expression of P-gp is the need of the hour. In one of the studies, an assembly incorporated BioPerine, isolated from piperine (active constituent of black pepper) into Poly lactic acid. The
chitosan-PEG coated BioPerine-PLA nanocarriers exhibited the release of BioPerine in a delayed manner in neutral environment, whereas the release was accelerated in a relatively basic environment, which indicates its dependability on the pH, for its release mechanism. This could point out to the variations in solubility or the differing dissolution rate. The determination of reactive oxygen species level was carried out on MDA-MB 453 cells, which when subjected to the optimized formulation alone, reported a little rise in ROS levels, but in addition to DOX, showed an effective increase in ROS levels, which further demonstrates the pH-dependent profile of ROS intensity. The co-delivered drugs proclaim successful inhibition of tumor cells through sustained release activity in suitable carrier, which provides an evidential support to target drug-resistance breast cancers (Pillai et al., 2020).

A combined nano-therapeutic system was developed by Zafar et al., which involved simultaneous loading of a frontline agent, docetaxel and an active constituent of Nigella sativa, thymoquinone (THQ), incorporating together into LNC. The resultant conjugate comprised of triglyceride core and PEG attached to DSPE as the shell. The PEG-DSPC complex is in turn loaded with a vitamin E derivative, referred to as TPGS. The elevated lipid concentrations resulted in a higher particle size, owing to the viscosity parameter, which limits the diffusion of the solvent. The entrapment efficiency and drug loading values of docetaxel and THQ of the optimized formulation were reported to be around 86.79% and 95.17%, respectively, whereas the drug loading percentage was observed to be approximately 1.19% and 2.61%, respectively. The rapid release of free drug from the complex at the beginning, might be associated with the presence of moieties at the nanocapsule surface, followed by a prolonged release rate, which further points to the gradual apoptotic effect.

The effective scavenging potential of free drugs was measured using the 2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH) assay, which reported significant antioxidant efficacy of THQ, individually as well as in combined form with docetaxel. Such consequence represents no major change in the functional stability of the molecule in presence of DOX. Hence, the proposed nano conjugated system provides a promising chemotherapeutic effect of the synergistic combination of DOX and THQ to tackle breast cancer (Zafar et al., 2020).

### 4.4. Thyroid cancer

Sorafenib (SOR) is an effective antitumor candidate, but due to an increased incidence of adverse events, it has limited applicability. All-trans retinoic acid (ATRA), an intermediate metabolite of vitamin A, is another compound responsible for inhibiting cell proliferation and metastasis and promoting cell differentiation and apoptosis. Li and group developed a formulation by incorporating SOR and all-trans retinoic acid into PEG linked PLGA polymer micelles in order to enhance the antitumor effect of SOR and thereby reduce its side effects. In vitro release studies showed slow and sustained drug release. The SOR release from PM/SOR and PM/(SOR + ATRA) was reported to be 61.3% and 62.4% while ATRA released from PM/ATRA and PM/(SOR + ATRA) was observed to be 56.3% and 63.9%, respectively. MTT assay was performed to evaluate the synergistic anticarcinogenic activity of SOR and ATRA on FTC-133 cells. 18.0 mmol L⁻¹ SOR and 70.0 mmol L⁻¹ ATRA when combined, proved to be an optimum concentration to illicit a desired synergistic antitumor effect. Tumor necrosis was seen in the group that received treatment with PM/(SOR + ATRA). Redifferentiation of thyroid cancer cells was determined by examining the NIS and Tg levels via immunofluorescence staining, which resulted in higher levels. The overall conclusion suggests that combined delivery of SOR and ATRA is a suitable therapeutic strategy to induce apoptosis, promote cell differentiation and suppress cell proliferation of FTC-133 thyroid cancer (Li et al., 2020).

NF-κB signaling plays a crucial role in cell proliferation, angiogenesis, survival, metastasis, invasion, and drug resistance. This study was approached in order to analyze the efficacy of NF-κB pathway inhibition in combination with docetaxel along with ionizing radiation in thyroid cancer cells. The outcomes showed a limited synergy when both docetaxel and ionizing radiation were used by either genetic or pharmacological pathway. Docetaxel and bortezomib, collectively led to a decreased in vitro invasion in only 8505C cells. SAHA, an effective candidate was found capable to reduce cell growth but the result is only limited to BCPAP cells. Hence, it was concluded that the NF-κB pathway inhibitors cannot be broadly accepted in cases of advanced thyroid cancer (Pozdeyev et al., 2015).

### 4.5. Pancreatic cancer

In a study conducted, a glutathione (GSH)-sensitive micelle (PAH-SS-PLGA) was formulated, which consisted of alpha-tocopheryl succinate (TOS) and curcumin, to target pancreatic cancer to provide combinational delivery. The objective was to improve the stability, solubility, bioavailability, and therapeutic efficacy. The optimized formulation of TOS or curcumin-loaded micelles was in the size range of 172.93 ± 1.1 nm and 194.17 ± 1.7 nm, respectively, and the encapsulation efficiency of the PAH-SS-PLGA micelle was reported to be 85% for TOS and 95.5% for curcumin. The results for in vitro cytotoxicity assays, using PAN02 pancreatic cancer cells, exhibited higher toxicity for nanoformulated TOS and/or curcumin as compared to free TOS and/or curcumin. Furthermore, it was confirmed that nanoformulated TOS or curcumin than free TOS or curcumin at a lower dosage showed better antiproliferative potential for the long term. The calculated CI values were observed to be less than one, which indicates a stronger synergistic effect for the nanoformulated drugs (PAH-SS-PLGA-TOS-curcumin) on cellular proliferation. Thus, it can be concluded that the selected drugs in combination can pave the way for enhancing the therapeutic efficacy and act as a treatment option for pancreatic cancer (Debele et al., 2020).

### 4.6. Lung cancer

Cisplatin, a platinum-containing compound, is involved with the cytotoxic effects in cancer. Epigallocatechin (EGCG), a green tea derivative, has been reported to enhance chemotherapy
and target therapy in lung cancer cells. Hence, a recent study performed by Ju Chen and associates, introduced a dual drug delivery system, that involved the formulation of EGCG/curcumin against IC50 value cancer cell lines of 25.01 and 6.652 mM, respectively, for 24 and 48 hours. Referring to the gene expression, Bax gene was associated with upregulation, as compared to the Bcl-2 gene, which underwent downregulation, as a result of the metformin treatment. A remarkable rise by 0.47- and 0.53-fold in PUMA gene expression was noted due to the treatment received by metformin and the combination, while expression of telomerase reverse transcriptase (hTERT), mammalian target of rapamycin (mTOR), and p53 experienced a huge decline. Moreover, an elevated apoptosis rate (p < .05) was achieved (about 24%) with the combination therapy and a successful synergistic potential was proven within a time period of 24 hours. The findings led to a conclusion that in contrast to individual, combined therapeutic treatments offer enhanced efficacy for prostate cancer (Eslami et al., 2020).

Inhibiting COX expression and identifying GLUT-1 receptors could be an efficient strategy to provide a suitable treatment option for prostate cancer. Considering these factors, a recent study was conducted, which analyzed a combination approach of EGCG and cisplatin in NPs would be a promising anticarcinogenic candidate for treatment of lung cancer (Chen et al., 2020).

Research was done to formulate PTX and triptolide-coloaded hybrid NPs (LPNs) to evaluate the therapeutic potential of the combination in human lung cancer cells, as a result of synergistic effect that offers reduced drug resistance. The characterization results reported that particle size was around 160 nm, PDI was observed to be less than 0.2 and zeta potential about −30 mV. Additionally, the entrapment efficiency of PTX and triptolide loaded in lipid-polymer hybrid NPs (LPNs) was over 85%, while the drug loading values calculated for PTX and triptolide were approximately 10% and 6%, respectively. Significant cytotoxicity results were obtained with dual drug loaded LPNs as compared to single drug loaded LPNs. With the use of combination approach, it was found that a synergistic effect was seen when the PTX:triptolide weight ratio was 5:3, which indicates it as a suitable combination. P/T-LPNs strongly inhibited tumor growth, which further proves the anticarcinogenic activity of the two drugs coloaded in LPNs, which can act as a therapeutic option for treatment of lung cancer (Liu et al., 2018).

The study was conducted, which analyzed a combination strategy, involving DOX and Hsp90 inhibitor ganetespib (GT), as a therapeutic alternative to combat non-small-cell lung cancer (NSCLC). DOX was selected as it initiates DNA damage and plays a key role in generation of reactive oxygen species (ROS) via redox-cycling and was combined with second-generation Hsp90 inhibitor, to exert a synergistic effect. As observed by encapsulation studies, enhanced stability, higher therapeutic efficacy, and reduced systemic toxicity, the resulting formulation showed higher drug payload. The combined drugs led to an active destruction of about 80% of lung cancer cells within 48 hours of incubation. The therapeutic effect of DOX was upgraded with the use of GT, through ROS production, which diminishes the cardiotoxicity levels of DOX to a little extent. It was clearly evident from the apoptosis and necrosis assays that GT had a synergistic effect on DOX’s activity. Therefore, the study came to a conclusion that offering such a combinational treatment of DOX and GT would be appropriate for targeting K-RAS driven NSCLC (Sulthana et al., 2017).

In one of the research, CD133+ specific peptide TISWPRP (TR) modified NLC (T-NLC) were prepared in order to target cancer cells along with cancer stem cells (CSCs) simultaneously as an effective therapeutic approach. The combination of PTX and Sal was utilized to achieve the desired response. The optimized formulation exhibited the size range of 128.73 ± 2.09 nm and zeta potential was observed to be −28.3 ± 0.4 mV. The TR-PEG-modified Sal loaded NLC (T-S-NLC) showed entrapment efficiency and drug loading values as 95.62 ± 1.46% and 1.02 ± 0.06%, respectively. The in vitro targeting effect revealed the capability of TR modified NLC in enhancing the drug internalization efficiency of CD133+CSCs. The in vitro targeting assay in CD133+CSCs revealed effective internalization efficiency. The proliferation inhibition action and cellular uptake in NCI-H1299 and S180 cell lines observed was successful in showing the in vitro tumor targeting effect of T-S-NLC + small peptide AEYLR-PEG-NLC. While examining in vivo tumor targeting action, a significant tumor accumulation was observed (Zhou et al., 2019).

4.7. Gastric cancer

Yang and coworkers synthesized hyaluronic acid (HA) containing lipid NPs coloaded with cisplatin plus SOR, using PEG as a mediator for the treatment of gastric cancer. The optimized formulation of HA-PEG-cisplatin and SOR coloaded NPs (H-CS-NPs) had a particle size of 173.2 ± 5.9 nm and zeta potential of −21.5 ± 3.2 mV. In vitro cytotoxicity of drug-loaded NPs and free drugs was tested on two types of gastric cancer cell lines: MKN28 and SGC7901 cells. H-CS-NPs effectively inhibited the tumor cell viability of cancer cell lines in contrast to the free drugs. The results interpreted by in vivo studies showed that NPs inhibited the tumor volume efficiently, which is attributed to the synergistic efficacy of two drugs (Yang et al., 2018).

4.8. Prostate cancer

Curcumin, a compound involved with obstruction in the cell proliferation along with metformin, which acts as a promising candidate in exhibiting anticarcinogenic response were selected to explore their synergistic outcome on lymph node carcinoma of the prostate (LNCaP) cancer cell line. The data with respect to the IC50 value, were reported to be 25.01 and 18.66 µM for 24 and 48 hours, respectively, whereas 9.904 and 6.652 mM, respectively, for 24 and 48 hours. Referring to the gene expression, Bax gene was associated with upregulation, as compared to the Bcl-2 gene, which underwent downregulation, as a result of the metformin treatment. A remarkable rise by 0.47- and 0.53-fold in PUMA gene expression was noted due to the treatment received by metformin and the combination, while expression of telomerase reverse transcriptase (hTERT), mammalian target of rapamycin (mTOR), and p53 experienced a huge decline. Moreover, an elevated apoptosis rate (p < .05) was achieved (about 24%) with the combination therapy and a successful synergistic potential was proven within a time period of 24 hours. The findings led to a conclusion that in contrast to individual, combined therapeutic treatments offer enhanced efficacy for prostate cancer (Eslami et al., 2020).

Inhibiting COX expression and identifying GLUT-1 receptors could be an efficient strategy to provide a suitable treatment option for prostate cancer. Considering these factors, a recent
study designed a liposomal nanocarrier, encapsulated with celecoxib and genistein, due to their antitumoral properties. The antiproliferative effects of single drugs induced around 20% reduction in cell viability of PC-3 cells, while approximately 75% decrease was seen in the case of combined liposomal formulation, which embarks on the combined capacity of drugs. The wound healing assay depicted a short duration therapeutic effect of celecoxib and genistein for over 24 hours, which was further diminished after prospective exposure, as opposed to their combination, which aids in long-term therapeutic benefits in inhibiting PC-3 cells. Reactive oxygen species were not formed when cells were treated with empty liposomes (EL), celecoxib liposomes (CL) and genistein (GL), while a 3-fold rise in production of ROS was obtained in the cells subjected to celecoxib-genistein complex treatment. Thus, the employed synergistic mechanism of the combined drugs acts in multiple ways to fight prostate cancer cells (Tian et al., 2019).

The combined mechanisms of chemotherapeutic strategies in combinatorial form have a suppressive effect on cancerous cells. In a recent study performed by Yuan and Gurunathan, a synergistic combination of celecoxib and genistein, as an adjuvant to doctaxel for castration resistant prostate cancer. 35% release was observed for doctaxel in phosphate buffer, while a 62% release was exhibited in acetate buffer medium. This depicts a dependency on the pH conditions for the nanocomplex to release the drug. The reduction in IC50 values along with the inclusion of siRNA highlights the combined efficacy of IL-8 linked siRNA to enhance the effect of doctaxel. The results demonstrate reliable results of the action of doctaxel against prostate cancer (Bulmahn et al., 2020).

**4.10. Cervical cancer**

Chemothapeutic strategies in combinatorial form have a synergistic capability of carboplatin and PTX formulated into lipidic nanocarriers, linked to FA in HeLa cell lines. The optimized formulation loaded with FA exhibited 170 nm particle size, whereas the unloaded one had a diameter of 121.3 nm. Carboplatin and PTX conjugated NPs showed no difference in the release profile of the drugs at variable pH environment, but folic acid complex showed elevated response in acidic conditions, compared to basic. Effective internalization of the optimized FA-NPs, observed in HeLa cells is an indicator of endocytosis and macropinocytosis. The nanocomplex was successfully localized within the tumor sites, which is attributed to the EPR mechanism. The formulation showed notable antiproliferative ability,
| S. No | Drug 1 | Drug 2 | Type of nanocarriers | Type of cancer | Types of study | Reference |
|-------|--------|--------|----------------------|----------------|---------------|-----------|
| 1     | Gemcitabine | Isocombretastatin A-4(isoCA-4) | Nanocomposites | Colon cancer | In vitro | (Maksimenko et al., 2014) |
| 2     | PTX | Gemcitabine | N-succinyl chitosan NPs | Colon cancer | In vitro/ in vivo | (Guo et al., 2015) |
| 3     | S-FU | BEZ-235 (Akt inhibitor) | NPs of layered double hydroxide | Colon cancer | In vitro | (Chen et al., 2014) |
| 4     | S-FU | Curcumin | Chitosan NPs | Colon cancer | In vitro | (Anitha et al., 2014) |
| 5     | S-FU | PTX gemcitabine | Poly(ε-caprolactone) NPs | Colon cancer | In vitro | (Ortiz et al., 2012) |
| 6     | DOX | PTX | Solid lipid nanoparticles | Colorectal cancer | In vitro | (Serpe et al., 2004) |
| 7     | PTX | DOX | Lipid-based NPs | Colorectal cancer | In vitro | (Agrawal et al., 2022a) |
| 8     | Diallyl trisulfide | DOX | Oxaliplatin | Liposome | Colorectal cancer | In vitro | (Agrawal et al., 2022b) |
| 9     | Diallyl Disulfide | DOX | pH-sensitive core-shell NPs | Gloma | In vitro | (Xu et al., 2018) |
| 10    | DOX | Lapatinib | Polymeric NPs | Breast cancer | In vitro | (Guo et al., 2020) |
| 11    | Cisplatin | Gemcitabine | PLGA-NP | Bladder cancer | In vitro/ in vivo | (Miao et al., 2014) |
| 12    | Rapamycin | Cisplatin | PLGA-NP | Melanoma | In vitro/ in vivo | (Guo et al., 2014) |
| 13    | DOX | Mitomycin C | Polymeric conjugate NPs | Hepatoma | In vitro/ in vivo | (Luo et al., 2015) |
| 14    | DOX | Verapamil | Hollow mesoporous silica NPs | Multidrug resistance tumor | In vitro | (Palanikumar et al., 2017) |
| 15    | DOX | Docetaxel | Janus NPs | Liver cancer | In vitro/ in vivo | (Zhang et al., 2018) |
| 16    | β-Lapachone | DOX | Polymeric NPs | Multidrug resistance tumor | In vitro/ in vivo | (Ye et al., 2017) |
| 17    | PTX | PTX | Surface charge-switchable nanosphere | Fibrosarcoma | In vitro | (Wang et al., 2019) |
| 18    | PTX | Sunitinib | Polymersmic micelle | Solid tumor | In vitro | (He et al., 2019) |
| 19    | DOX | Combretastatin A4 | Polypeptide Nanocarriers | Breast cancer | In vitro/ in vivo | (Dong et al., 2015) |
| 20    | Sal | PTX | Prodrug NPs | Cancer stem cells | In vitro | (Liang et al., 2018) |
| 21    | DOX | PTX | Polymeric NPs | Breast cancer | In vitro | (Muntimadugu et al., 2016) |
| 22    | DOX | Curcumin | Lipid-coated polymeric NP | Osteosarcoma | In vitro/ in vivo | (Wang et al., 2016) |
| 23    | Borneol | DOX | Dendrimers | Brain tumor | In vitro | (Han et al., 2018) |
| 24    | Oxaliplatin prodrug | Docetaxel | PEGylated | PEGylated nanocarriers | Colon cancer | In vitro/ in vivo | (Deng et al., 2021) |
| 25    | PTX | Embelin | TRAIL plasmid | Liposomes c | Breast cancer | In vitro/ in vivo | (Ghos et al., 2021) |
| 26    | DOX | Gemicitabine | Docetaxel | Liposome nanocomplexes | Breast cancer | In vitro/ in vivo | (Ghos et al., 2021) |
| 27    | DOX | Celecoxib | Glycol chitosan pH-sensitive NPs | Breast cancer | In vitro/ in vivo | (Ghos et al., 2021) |
| 28    | Vinorelbine | Tetrandrine | Liposomes with modified PEG conjugates | Brain glioma | In vitro/ in vivo | (X-T. Li et al., 2016) |
| 29    | Vinorelbine | Tetrandrine | Liposomes modified with RGD (arginine glycine aspartic acid) tripeptide | Brain glioma | In vivo | (Li et al., 2019) |
| 30    | Daunorubicin | Honokiol | Lactoferrin (Lf)-modified liposome | Brain glioma | In vitro/ in vivo | (Liu et al., 2017) |
| 31    | Transferrin-modified vinristine | Tretinoin | Liposomes | Brain glioma | In vitro/ in vivo | (Song et al., 2017) |
| 32    | Cisplatin | DOX | Polymeric NPs | Breast cancer | In vitro/ in vivo | (Deng et al., 2014) |
| 33    | siRNA | Cisplatin | PLGA NPs | Prostate cancer | In vitro/ in vivo | (Xu et al., 2013) |
| 34    | miR-200c | Docetaxel | PEG-PEP-PCL NPs | Gastric cancer | In vitro/ in vivo | (Liu et al., 2013) |
| 35    | PTX | Lonidamine | mPEGb-PCLeb-PPEEA NPs | Ovarian cancer | In vitro | (Palanikumar et al., 2011a). |
| 36    | Plk1-specific siRNA | DOX | mPEGb-PCLeb-PPEEA NPs | Breast Cancer | In vitro/ in vivo | (Sun et al., 2011) |
| 37    | Combretastatin A4 | PTX | Polymeric NPs | Lung cancer | In vitro/ in vivo | (Wang & Ho, 2010) |
| 38    | Doxorubicin | Loperamide | PLGA NPs | Glioblastoma | In vivo | (Gelperina et al., 2010) |
| 39    | Cisplatin | Docetaxel | PLGA-PLA NPs | Prostate cancer | In vitro | (Kolshetti et al., 2010) |
| 40    | DOX | P-glycoprotein siRNA | Silica NPs | Cervical tumor | In vitro | (Meng et al., 2010) |
| 41    | PTX | Alendronate | Dendrimers | Bone metastases | In vitro | (Clementi et al., 2011) |
| 42    | Cisplatin | DOX | Dendrimers | Prostate cancer | In vitro | (Kolshetti et al., 2010) |
| 43    | PTX | Thymoquinone | Dendrimers | Breast cancer | In vitro | (Soni et al., 2015) |
| 44    | Ionidamine | PTX | Dendrimers | Breast cancer | In vitro | (Milane et al., 2011b) |
| 45    | Cisplatin | PTX | Dendrimers | Ovarian cancer | In vitro/ in vivo | (Desale et al., 2013) |
| 46    | DOX | Verapamil | Dendrimers | Prostate carcinoma | In vitro/ in vivo | (Wang & Ho, 2010) |
| 47    | PTX | Gemcitabine | Dendrimers | Breast carcinoma | NA | (Song et al., 2009) |
| 48    | DOX | PTX | Carbon nanotubes | Pancreatic | In vitro | (Aryal et al., 2010) |
| 49    | DOX | Carbon nanotubes | Head-neck cancer | In vitro | (Colley et al., 2014) |
| 50    | Verapamil | Carbon nanotubes | Hepatocellular carcinoma | In vitro | (Anajafa et al., 2017) |
| 51    | PTX | Curcumin | Carbon nanotubes | Head-neck cancer | In vitro | (Thambi et al., 2012) |

PTX: Paclitaxel; S-FU: S-Florouracil; Sal: Salinomycin; DOX: Doxorubicin.
thereby acting as a reliable candidate for cervical cancer (Wang, 2020).

In a study conducted by Murugesan et al., constituent of curcumin, ST06 was loaded into the surface of silver NPs in order to investigate the synergistic tumor inhibiting mechanism. The diametric size of NPs was found to be between 73.48 to 74.52 nm, while the PDI and zeta potential were calculated as 0.2 and −35.3 mV, respectively. The inhibition rate in HeLa cell line was enhanced with increase in dosage of formulation. There was a decline in EAC tumor volumetric values on administration of optimized NPs, in contrast to the control. Aspartate transaminase (AST) and alanine transaminase (ALT) levels were not affected by the formulation, whereas urea levels were elevated following treatment. The results are representative of the antitumor efficacy and anti-proliferative response against Ehrlich’s ascites carcinoma (EAC) tumors and HeLa cells (Murugesan et al., 2019) (Table 2).

5. Discussion
Anticancer chemotherapy, radiotherapy, and surgery have played a pivotal role in managing and treating the different types of cancers. However, these therapeutic approaches have failed to achieve significant clinical outcomes, and relapse and side effects were commonly reported (Conlon et al., 2019). Therefore, the combined drug delivery system is gaining popularity to overcome the shortcomings of single drug delivery and for better therapeutic outcomes. Thus, attempts were made to combine as chemotherapeutic with chemotherapeutic, chemotherapeutic with herbal drug, herbal drug with herbal drug, chemotherapeutic with immunotherapeutic drug for the depletion of tumor cells and to, prevent tumor relapse, and ultimately increase the clinical response (Da Silva et al., 2016). When these combination approaches are being used, pharmacokinetic as well as pharmacodynamic synergistic effect are observed. It is further important to understand that, nowadays, chemotherapeutic and immunotherapeutic drugs are gaining more attention because this combination effectively reduces the level of cancerous T regulatory cells and creates an immune-rich and favorable environment for the anticancer effect of drugs. Clinical translation of preclinical study determines the success or rationale of the research. Considering the nano-oncotherapeutics, CYT-6091 which consists of recombinant TNF attached with the PEGylated, 27 was the first nano formulation that was evaluated among patients of advanced solid tumor (NCT00356980, NCT00436410). The same formulation has been successfully studied against breast cancer. Apart from the CYT-6091, AuroLase is the FDA-approved nanoformulation and has been studied among the patients of lung tumor and head-neck carcinoma (Beik et al., 2019).

Hence, looking into the risk-benefit ratio of drugs combination of chemotherapy and immunotherapy appears to be more rational and effective, but at the same time, drug combination increases the cost of treatment frequency of dosing and exhibits serious side effects (Yasmeen et al., 2021). Hence, to overcome such an issue, low-dose immunotherapeutic or chemotherapeutic drugs were initially used, but the pharmacokinetic limitation was still prevalent (Da Silva et al., 2016).

Hence, to overcome these limitations, nanocarrier-based drug delivery is used to improve the pharmacological effect and to reduce the pharmacokinetic limitation and side effects (Correia et al., 2021). Furthermore, the combinatorial nanocarrier system is being used in the treatment of cancer to achieve precise therapeutic value through dual drug delivery. As discussed above, there are a variety of combination approaches have been reported for treatment of different cancers, such as colon cancer, colorectal cancer, breast cancer, bladder cancer, melanoma, brain tumor, lung cancer, etc. Combinatorial nanocarrier-based drug delivery offers certain benefits, such as rationale integration of drugs that cumulatively deliver the drug at the target site with a distinct selection of normal and cancerous cells (Wang & Huang, 2020). The clinical importance of nanocarrier-based chemotherapeutic drug delivery is evident from the studies where gold NPs are under clinical trial for advanced solid tumors (NCT00356980, NCT00436410). Moreover, for the treatment of ductal carcinoma and breast cancer, a gold NP ‘AuroLase’ has been approved by the USFDA (NCT00848042, NCT01679470) (Beik et al., 2019).

6. Future prospect and conclusion
No doubt, currently number of anticancer drugs are used as nanomedicine and monotherapy with a targeted therapy approach. However, despite being their wide spread use, these agents failed to exhibit complete remission. Hence, attempts were made use combination of nanomedicine that exhibit better clinical outcome and overcome the possible drug resistance. Despite being a potent and futuristic therapeutic option, nanocarriers for the dual delivery of anticancer drug development is a challenging task and prediction for the reduction in toxicity and targeted drug delivery at a predetermined rate is necessary. Furthermore, it is also crucial to predict, determine and validate how the combinatorial nanocarriers will behave in the tumor microenvironment. Hence, it can be concluded that combinatorial onconanotherapeutics would be an emerging and clinically relevant therapeutic modality for managing and treating cancer. There also exists an unmet and urgent need for the rationale development of a combinatorial onconanotherapeutics system that can be taken from the preclinical to the clinical phase of trials so that more and more chemotherapeutically treated patients can be benefited from this novel treatment approach. Additionally, a well-designed and fabricated nanocarrier can be used for effective gene delivery. In the coming days, this approach will be a more viable and versatile strategy for improving patients’ clinical outcomes and quality of life. Furthermore, it has also been concluded that combinatorial nanocarriers could be a way toward the development of personalized theranostic medicine where different nanocarriers loaded with anticancer drugs can be rationally designed by integrating the expertise of pharmaceutical engineers and biochemists’ oncologists, and clinicians. However, a major limitation for the clinical use of these combinational nanomedicine is the toxicity and hence, these drugs must be
fabricated in such a way that they can exhibit multifactorial mechanism of action with minimum toxicity. Thus, combinatorial nanocarrier-based theranostic medicine in the coming time may transform and revolutionize the management and treatment of cancer.

Disclosure statement
No potential conflict of interest was reported by the authors.

Funding
This research work was funded by Institutional Fund Projects under grant no. (IFPDP-212-22). Therefore, the authors gratefully acknowledge technical and financial support from Ministry of Education and Deanship of Scientific Research (DSR), King Abdulaziz University (KAU), Jeddah, Saudi Arabia.

ORCID
Nabil A. Alhakamy http://orcid.org/0000-0002-3826-1519
Ashif Iqubal http://orcid.org/0000-0003-4694-4851
Javed Ali http://orcid.org/0000-0001-5308-0655
Sanjana Baboota http://orcid.org/0000-0003-1508-6786

References
Al-Lazikani B, Banerji U, Workman P. (2012). Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 30:679–92. https://doi.org/10.1038/nbt.2284
Allmørdi H, Greish K, Barzegar-Fallah A, et al. (2018). Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity. Int J Nanomedicine 13:7771–87. https://doi.org/10.2147/IJN.S187089
Alrumaihi F, Khan MA, Babiker AY, et al. (2022a). Lipid-based nanoparticle dual-drug delivery. Small 6:1442–8. https://doi.org/10.1002/smll.201000631
Alrumaihi F, Khan MA, Babiker AY, et al. (2022b). Lipid-based nanoparticles: formulation of diallyl trisulfide chemosensitizes the growth inhibitory activity of doxorubicin in colorectal cancer model: a novel in vitro, in vivo and in silico analysis. Molecules 27:2192. https://doi.org/10.3390/molecules27072192
Anajafi T, Yu J, Sedigh A, et al. (2017). Nuclear localizing peptide-conjugated, redox-sensitive polymersomes for delivering curcumin and doxorubicin to pancreatic cancer microtumors. Mol Pharm 14:1916–28. https://doi.org/10.1021/acs.molpharmaceut.7b00014
Anitha A, Sreeranganathan M, Chennazhi KP, et al. (2014). In vitro combinatorial anticancer effects of 5-fluorouracil and curcumin loaded N,O-carboxymethyl chitosan nanoparticles toward colon cancer and in vivo pharmacokinetic studies. Eur J Pharm Biopharm 88:238–51. https://doi.org/10.1016/j.ejpb.2014.04.017
Aryal S, Hu C-MJ, Zhang L. (2010). Combinatorial drug conjugation enables nanoparticle dual-drug delivery. Small 6:1442–8. https://doi.org/10.1002/smll.201000631
Ayoub NM. (2021). Editorial: novel combination therapies for the treatment of solid cancers. Front Oncol 11:708943. https://doi.org/10.3389/fonc.2021.708943
Beik J, Khateri M, Khorosravi Z, et al. (2019). Gold nanoparticles in combinatorial cancer therapy strategies. Coord Chem Rev 387:299–324. https://doi.org/10.1016/j.ccr.2019.02.025
Blagosklonny MV. (2008). “Targeting the absence” and therapeutic engineering for cancer therapy. Cell Cycle 7:1307–1312. https://doi.org/10.1046/j.1c7e.1.06250
Bolat ZB, Islek Z, Demir BN, et al. (2020). Curcumin- and pipeline-loaded emulsomes as combinational treatment approach enhance the anticancer activity of curcumin on HCT116 colorectal cancer model. Front Bioeng Biotechnol 8:50. https://doi.org/10.3389/fbioe.2020.00050
Bukowska B, Gajek A, Marcza K. (2015). Two drugs are better than one. a short history of combined therapy of ovarian cancer. Contemp Oncol (Pozn) 19:350–353. https://doi.org/10.5114/wo.2014.43975
Bulmahn JC, Kutscher HL, Cwiklinski K, et al. (2020). A multimodal theranostic nanoformulation that dramatically enhances doctaxel efficacy against castration resistant prostate cancer. J Pharm Sci 109:2874–2883. https://doi.org/10.1016/j.xphs.2020.06.004
Cai L, Xu G, Shi C, et al. (2015). Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: a synergistic combination nanotherapy for ovarian cancer treatment. Biomaterials 37:456–468. https://doi.org/10.1016/j.biomaterials.2014.10.044
Chen J, Shao R, Li L, et al. (2014). Effective inhibition of colon cancer cell growth with MglAlpha-layered double hydroxide (LDH) loaded S-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways. Int J Nanomedicine 9:3403–11. https://doi.org/10.2147/IJN.S61633
Chen Yi, Wang ZW, Lu TL, et al. (2020). The synergistic anticancer effect of dual drug- (cisplatin/epigallocatechin gallate) loaded gelatin nanoparticles for lung cancer treatment. J Nanomater 2020:1–15. https://doi.org/10.1155/2020/9181549
Chou T-C. (2010 ). Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440–446. https://doi.org/10.1158/0008-5472.CAN-09-1947
Clementi C, Miller K, Mero A, et al. (2011). Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol Pharm 8:1063–72. https://doi.org/10.1021/mp2001445
Colley HE, Hearden V, Avila-Ollas M, et al. (2014). Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D in vitro evaluation. Mol Pharm 11:1176–88. https://doi.org/10.1021/mp400610b
Colombo M, Marabese M, Vargiu G, et al. (2020). Activity of birapinarat, a SMAC mimetic compound, alone or in combination in NSCLCs with different mutations. Front Oncol 10:532292. https://doi.org/10.3389/fonc.2020.532292
Conlon KC, Miljkovic MD, Waldmann TA. (2019). Cytokines in the treatment of cancer. J Interferon Cytokine Res 39:6–21. https://doi.org/10.1089/jir.2018.0019
Correia AS, Gärntner F, Vale N. (2021). Drug combination and repurposing for cancer therapy: the example of breast cancer. Helicon 7:e05984. https://doi.org/10.1016/j.helicon.2021.e05984
Croce CM. (2008). Oncogenes and cancer. N Engl J Med 358:502–511. https://doi.org/10.1056/NEJMr0723567
Da Silva CG, Rueda F, Löwik CW, et al. (2016). Combinatorial prospects of nano-targeted chemoimmunotherapy. Biomaterials 83:308–320. https://doi.org/10.1016/j.biomaterials.2016.01.006
Dawwal A, Baldi A, Kumar Narang R. (2018). Nanoparticles as carriers for drug delivery in cancer. Artif Cells Nanomed Biotechnol 46:295–305. https://doi.org/10.1089/acn.2018.1457039
Davis ME, Zuckerman JE, Choi CHJ, et al. (2010). Evidence of RNAi in cells: 2D and 3D in vitro evaluation. Mol Pharm 8:1063–72. https://doi.org/10.1021/mp2001445
Debele TA, Wu HC, Wu SR, et al. (2020). A multimodal theranostic nanoformulation that dramatically enhances doctaxel efficacy against castration resistant prostate cancer. J Pharm Sci 109:2874–2883. https://doi.org/10.1016/j.xphs.2020.06.004
Deng Z, Wang N, Ai F, et al. (2021). Nanomaterial-mediated platinum drug-based combinational cancer therapy. View 2:20200030. https://doi.org/10.1089/jir.2018.0019
Grollman A, Kutscher HL, Workman P. (2012). Combinatorial drug therapy in cancer. Artif Cells Nanomed Biotechnol 40:2883. https://doi.org/10.3389/fbioe.2020.00050
Deng X, Cao M, Zhang J, et al. (2014). Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials 35:4333–44. https://doi.org/10.1016/j.biomaterials.2014.02.006
Deng Z, Wang N, Ai F, et al. (2021). Nanomaterial-mediated platinum drug-based combinational cancer therapy. View 2:20200030. https://doi.org/10.1089/jir.2018.0019
Desale SS, Cohen SM, Zhao Y, et al. (2013). Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer. J Control Release 171:339–48. https://doi.org/10.1016/j.jconrel.2013.04.026
Desale SS, Soni KS, Romanova S, et al. (2015). Targeted delivery of platinum-taxane combination therapy in ovarian cancer. J Control Release 220:651–659. https://doi.org/10.1016/j.jconrel.2015.09.007

Diab T, AlKafaas SS, Shalaby Th, Hissen M. (2020). Dexamethasone simulates the anticancer effect of nano-formulated paclitaxel in breast cancer cells. Bioorg Chem 99:103792. https://doi.org/10.1016/j.bioorg.2020.103792

Ding Y, Yu S, Zhang R, et al. (2017). Precision combination therapy for triple negative breast cancer via biomimetic polydopamine polymer core-shell nanostructures. Biomaterials 113:243–252. https://doi.org/10.1016/j.biomaterials.2016.10.053

Dong Y, Yang J, Liu H, et al. (2015). Site-specific drug-releasing polypeptide nanocarriers based on dual-pH response for enhanced therapeutic efficacy against drug-resistant tumors. Theranostics 5:890–904. https://doi.org/10.7150/thno.11821

Eslami SS, Jafari D, Montazeri H, et al. (2020). Combination of curcumin and metformin inhibits cell growth and induces apoptosis without affecting the cell cycle in LNCaP prostate cancer cell line. Nutr Cancer 0:1–14. https://doi.org/10.1080/01635581.2020.1783327

Falzone L, Salomone S, Libra M. (2018). Evolution of cancer pharmacology and therapeutics. Nat Rev Drug Discov 16:89–100. https://doi.org/10.1038/nrd.2016.238

Frei E, Karon M, Levin RH, et al. (1965). The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26:642–656. https://doi.org/10.1182/blood.V26.5.642.642

Gavas S, Quazi S, Karpiński TM. (2021). Nanoparticles for cancer therapy: current progress and challenges. Nanoscale Res. Lett 16:1–21. https://doi.org/10.1186/s11671-021-03628-6

Gelperina S, Maksimenko O, Khaltansky A, et al. (2010). Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm 74:157–63. https://doi.org/10.1016/j.ejpb.2009.09.003

Ghosh S, Javia A, Shetty S, et al. (2021). Triple negative breast cancer and non-small cell lung cancer: clinical challenges and nano-formulation approaches. J Control Release 337:27–58. https://doi.org/10.1016/j.jconrel.2021.07.014

Ghosh SK, Yigit MV, Uchida M, et al. (2014). Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma. Int J Cancer 134:1758–1766. https://doi.org/10.1002/ijc.28499

Goodman LS, Wintrobe MM. (1946). Nitrogen mustard therapy. J Am Med Assoc 132:126–132. https://doi.org/10.1001/jama.1946.02870380008004

 Gowda R, Kardos G, Sharma A, et al. (2017). Nanoparticle-based celecoxib and plumbagin for the synergistic treatment of melanoma. Mol Cancer Ther 16:440–452. https://doi.org/10.1158/1535-7163.MCT-16-0285

Guo S, Lin CM, Xu Z, et al. (2014). Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 8:4996–5009. https://doi.org/10.1021/nn5010815

Guo X-Y, Wang P, Du Q-G, et al. (2015). Paclitaxel and gemcitabine combinational drug-loaded mucoadhesive delivery system in the treatment of colon cancers. Drug Res (Stuttg) 65:199–204. https://doi.org/10.1055/s-0034-1375665

Guo Z, Sui X, Ma M, et al. (2020). pH-Responsive charge switchable PEGylated e-poly-l-lysin polymeric nanoparticles-assisted combination therapy for improving breast cancer treatment. J Control Release 326:350–364. https://doi.org/10.1016/j.jconrel.2020.07.030

Han S, Zheng H, Lu Y, et al. (2018). A novel synergetic targeting strategy for glioma therapy employing borneol combination with angiopep-2-modified, DOX-loaded PAMAM dendrimer. J Drug Target 26:86–94. https://doi.org/10.1080/1061186X.2017.1344849

He J, Xiao H, Li B, et al. (2019). The programmed site-specific delivery of the angiostatin sunitinib and chemotherapeutic paclitaxel for highly efficient tumor treatment. J Mater Chem B 7:4953–4962. https://doi.org/10.1039/C9TB01159E

Hrkach J, Von Hoff D, Mukkaram Ali M, et al. (2012). Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmaceutical profile. Sci Transl Med 4:128ra39. https://doi.org/10.1126/scitranslmed.3003651

Hsu J-L, Leu W-J, Hsu L-C, et al. (2020). Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling. Front Oncol 10:1274. https://doi.org/10.3389/fonc.2020.01274

Hu Y, Zhang K, Zhu X, et al. (2021). Synergistic inhibition of drug-resistant colon cancer growth with PI3K/mTOR dual inhibitor BEZ235 and nano-eminsonulated paclitaxel via reducing multidrug resistance and promoting apoptosis. Int J Nanomedicine 16:2173–2186. https://doi.org/10.2147/IJN.S290731

Huang J, Xu Y, Xiao H, et al. (2019). Core–shell distinct nanodrug showing on-demand sequential drug release to act on multiple cell types for synergistic anticancer therapy. ACS Nano 13:7036–7049. https://doi.org/10.1021/acsnano.9b02149

Iqubal MK, Chaudhuri A, Iqubal A, et al. (2020). Targeted delivery of natural bioactives and lipid-nanocargos against signaling pathways involved in skin cancer. Curr Med Chem 27:1–33. https://doi.org/10.2174/092986732766620104151752

Iqubal MK, Iqubal A, Anjum H, et al. (2021a). Determination of in vivo virtue of dermal targeted combinatorial lipid nanocollodial based formulation of 5-fluorouracil and resveratrol against skin cancer. Int J Pharm 610:12179. https://doi.org/10.1016/j.ijpharm.2021.04.007

Ismail M, Khan S, Khan F, et al. (2020). Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy. BMC Cancer 20:7. https://doi.org/10.1186/s12885-020-06855-9

Jones PA, Baylin SB. (2007). The epigenomics of cancer. Cell 128:683–692. https://doi.org/10.1016/j.cell.2007.01.029

Ju Yang E, Wu C, Liu Y, et al. (2016). Revisiting non-cancer drugs for cancer therapy. Curr Top Med Chem 16:2144–2155. https://doi.org/0.1016/j.msec.2019.01.066

Kalyane D, Raval N, Maheshwari R, et al. (2019). Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C Mater Biol Appl 98:1252–1276. https://doi.org/10.1016/j.msec.2019.01.066

Kawada K, Taketo MM. (2011). Significance and mechanism of lymph node metastasis in cancer progression. Cancer Res 71:1214–1218. https://doi.org/10.1158/0008-5472.CAN-10-3277

Kent R, Huber B. (1999). Gertrude Belle Elion (1918-99). Nature 398:380. https://doi.org/10.1038/18790

Koliishtetti N, Dhar S, Valencia PM, et al. (2010). Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A 107:17939–44. https://doi.org/10.1073/pnas.1011368107

Li C, Han X. (2020). Co-delivery of dacarbazine and all-trans retinoic acid (ATRA) using lipid nanoformulations for synergistic antitumor efficacy against malignant melanoma. Nanoscale Res Lett 15:1672–1678. https://doi.org/10.1186/s11671-021-03293-3

Li S, Dong S, Xu W, et al. (2020). Polymer nanoformulation of sorafenib and all-trans retinoic acid for synergistic inhibition of thyroid cancer. Front Pharmacol 10:1676. https://doi.org/10.3389/fphar.2019.01676

Li W, Zhang H, Assaraf YG, et al. (2016). Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms
and novel therapeutic drug strategies. Drug Resist Updat 27:14-29. https://doi.org/10.1016/j.drup.2016.05.001

Li X-T, Tang W, Jiang Y, et al. (2016). Multifunctional targeting vinorelbine plus tetradrine liposomes for treating brain glioma along with eliminating glioma stem cells. Oncotarget 7:24604–22. https://doi.org/10.18632/oncotarget.8360

Li X-T, Tang W, Xie H-J, et al. (2019). The efficacy of RGD modified liposomes with vinorelbine plus tetradrine in treating resistant brain glioma. J Liposome Res 29:21–34. https://doi.org/10.1080/08982014.2017.1408649

Li Z, Tan S, Li S, et al. (2017). Cancer drug delivery in the nano era: an overview and perspectives (Review). Oncol Rep 38:611–624. https://doi.org/10.3892/or.2017.5718

Liang D-S, Liu J, Peng T-X, et al. (2018). Vitamin E-based redox-sensitive salinomycin prodrug-nanoparticles with paclitaxel loaded for cancer targeted and combined chemotherapy. Colloids Surf B Biointerfaces 172:506–516. https://doi.org/10.1016/j.colsurfb.2018.08.063

Liu J, Cheng H, Han L, et al. (2018). Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-colored lipid-polymer hybrid nanoparticles. Drug Des Devel Ther 12:3199–3209. https://doi.org/10.2147/DDDT.S172199

Liu Q, Li R-T, Qian H-Q, et al. (2013). Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. Biomaterials 34:7191–203. https://doi.org/10.1016/j.biomaterials.2013.06.004

Liu S, Zhang S-M, Ju R-J, et al. (2017). Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma. Eur J Pharm Sci 106:185–197. https://doi.org/10.1016/j.ejps.2016.09.024

Luo S, Gu Y, Zhang Y, et al. (2015). Precise ratiometric control of dual drugs through a single macromolecule for combination therapy. Mol Pharm 12:2318–2327. https://doi.org/10.1021/mp500867g

Maieron L, Daßler-Penker J, Sun L, Egeblad M. (2022). Innate immunity and cancer pathophysiology. Annu Rev Pathol 17:425–457. https://doi.org/10.1146/annurev-pathmed-032221-115501

Maksimenko A, Alami M, Zouhiri F, et al. (2014). Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy. ACS Nano 8:2018–2032. https://doi.org/10.1021/nn500517a

Md S, Alhakamy NA, Aldawarsi HM, et al. (2020). Formulation design, statistical optimization, and in vitro evaluation of a naringenin nanocomplex for effective breast cancer therapy. J. Nanoparticle Res 22:6601–6611. https://doi.org/10.1002/adfm.201401076

Meng H, Liong M, Xia T, et al. (2010). Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA noemulsion to enhance apoptotic activity in a549 lung cancer cells. Int J Nanomedicine 5:131–140. https://doi.org/10.2147/IJN.S26401

Murugesan K, Koroth J, Srinivasan PP, et al. (2019). Effects of green synthesized silver nanoparticles (ST06-AgNPs) using curcumin derivative (ST06) on human cervical cancer cells (HeLa) in vitro and EAC tumor bearing mice models. Int J Nanomedicine 14:5257–5270. https://doi.org/10.2147/IJN.S202440

Narayan RS, Molenar P, Teng J, et al. (2020). A cancer drug atlas enables synergetic targeting of independent drug vulnerabilities. Nat. Commun 11:1–14. https://doi.org/10.1038/s41467-020-16735-2

Nasr S, Rady M, Gomaa I, et al. (2019). Ethosomes and lipid-coated chitosan nanoparticles for skin delivery of a chlorophyll derivative: a potential treatment of squamous cell carcinoma by photodynamic therapy. Int J Pharm 568:118228. https://doi.org/10.1016/j.ijpharm.2019.118528

Nichemateniya SN, Tarusico TG, Barney DL, Exon JH. (2006). A review of the effects and mechanisms of polyphenolics in cancer. Crit Rev Food Sci Nutr 46:161–183. https://doi.org/10.1080/10408390591000541

O’Brien MER, Wigler N, Inbar M, CAELYX Breast Cancer Study Group, et al. (2004). Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol Off J Eur Soc Med Oncol 15:440–449., https://doi.org/10.1093/annonc/mdh097

Ortiz R, Prados J, Melguizo C, et al. (2012). 5-Fluorouracil-loaded poly-(caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer. Int J Nanomedicine 7:95–107. https://doi.org/10.2147/IJN.S26401

Palanikumar L, Jeena MT, Kim K, et al. (2017). Spatiotemporally and sequentially-controlled drug release from polymer gatekeeper–hollow silica nanoparticles. Sci Rep 7:46540. https://doi.org/10.1038/srep46540

Palazolo S, Bayda S, Hadla M, et al. (2018). The clinical translation of organic nanomaterials for cancer therapy: a focus on polymer nanoparticles, micelles, liposomes and exosomes. Curr Med Chem 25:4224–4268. https://doi.org/10.2174/0929867324666170830113755

Palmer AC, Chidley C, Sorger PK. (2019). A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug addictivity. Elife 8:1–36. https://doi.org/10.7554/elife.50036

Papac RJ. (2010). Origins of cancer therapy. Yale J Biol Med 74:391–8. https://doi.org/10.1093/yjbm/74.4.391

Pillai SC, Borah A, Jindal A, et al. (2020). BioPerine encapsulated nanof ormulation for overcoming drug-resistant breast cancers. Asian J Pharm Sci 15:701–712. https://doi.org/10.1016/j.ajps.2020.04.001

Porter AP, Papaioannou A, Malliri A. (2016). Deregulation of Rho GTPases in cancer cell line. Eur J Pharm Biopharm 58:673–680. https://doi.org/10.1016/j.ejpb.2004.03.026

Pozdeyev N, Berlinberg A, Zhou Q, et al. (2015). Targeting the NF-κB pathway as a combination therapy for advanced thyroid cancer. PLoS One 10:e0134901–12. https://doi.org/10.1371/journal.pone.0134901

Riley RS, Day ES. (2017). Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9:1–25. https://doi.org/10.1002/wnan.1449

Serpe L, Catalano MG, Cavalli R, et al. (2004). Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 58:673–680. https://doi.org/10.1016/j.ajps.2004.03.026

Shi W, Zhang S, Ma D, et al. (2020). Targeting SphK2 reverses acquired resistance of regorafenib in hepatocellular carcinoma. Front Oncol 10:694–17. https://doi.org/10.3389/fonc.2020.00694

Siegel RL, Miller KD, Fuchs HE, Jemal A. (2022). Cancer statistics, 2022. CA Cancer J Clin 72:7–33. https://doi.org/10.3322/caac.21708

Song X-L, Liu S, Jiang Y, et al. (2017). Targeting vincristine plus tetradrine liposomes modified with DSPE-PEG2000 transferrin in treatment of brain glioma. Eur J Pharm Sci 96:129–140. https://doi.org/10.1016/j.ejps.2016.09.024

Song XR, Cai Z, Zheng Y, et al. (2009). Reversion of multidrug resistance of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. Int J Pharm 34:453–464. https://doi.org/10.1016/j.ijpharm.2019.118528

Song XR, Cai Z, Zheng Y, et al. (2009). Reversion of multidrug resistance of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. Int J Pharm 34:453–464. https://doi.org/10.1016/j.ijpharm.2019.118528

Sonir S, Kaur J, Tikoo K. (2015). Dual drug-loaded paclitaxel–thymoquinone nanoparticles for effective breast cancer therapy. J. Nanoparticle Res 17:1–12.
Sulthana S, Banerjee T, Kallu J, et al. (2017). Combination therapy of NSCLC using Hsp90 inhibitor and doxorubicin carrying functional nanoceria. Mol Pharm 14:875–884. https://doi.org/10.1021/acs.molpharmaceut.6b01076

Sun T-M, Du J-Z, Yao Y-D, et al. (2011). Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 5:11936–11948. https://doi.org/10.1021/acsnano.100349h

Tham HP, Xu K, Lim WQ, Chen, et al. (2018). Microneedle-assisted topical delivery of photodynamically active mesoporous formulation for combination therapy of deep-seated melanoma. ACS Nano 12:11936–11948. https://doi.org/10.1021/acsnano.100349h

Thambi T, Deepagan VG, Ko H, et al. (2012). Bioreducible polymersomes for intracellular dual-drug delivery. J Mater Chem 22:22028–22036. https://doi.org/10.1039/c2jm34546c

The ASCO Post Staff. 2020. 2020 FDA Approvals of Drugs for Cancer Treatment [WWW Document]. Harborside. URL https://ascopost.com/issues/december-25-2020/2020-fda-approvals-of-drugs-for-cancer-treatment/ (accessed 6.20.22).

Tian J, Guo F, Chen Y, et al. (2019). Nanoporous microporous encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation. Cancer Lett 448:1–10. https://doi.org/10.1016/j.canlet.2019.01.002

Tolcher AW, Mayer LD. (2018). Improving combination cancer therapy: the CombiPlex® development platform. Future Oncol 14:1317–1332. https://doi.org/10.2217/fon-2017-0607

Tsakiris N, Fauvet F, Ruby S, et al. (2020). Combined nanomedicines targeting colorectal cancer stem cells and cancer cells. J Control Release 326:387–395. https://doi.org/10.1016/j.jconrel.2020.07.025

Tuli HS, Mittal S, Aggarwal D, et al. (2021). Path of Silibinin from diet or-cancer-treatment/ (accessed 6.20.22).

Tian J, Guo F, Chen Y, et al. (2019). Nanoporous microporous encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation. Cancer Lett 448:1–10. https://doi.org/10.1016/j.canlet.2019.01.002

Tolcher AW, Mayer LD. (2018). Improving combination cancer therapy: the CombiPlex® development platform. Future Oncol 14:1317–1332. https://doi.org/10.2217/fon-2017-0607

Tsakiris N, Fauvet F, Ruby S, et al. (2020). Combined nanomedicines targeting colorectal cancer stem cells and cancer cells. J Control Release 326:387–395. https://doi.org/10.1016/j.jconrel.2020.07.025

Tuli HS, Mittal S, Aggarwal D, et al. (2021). Path of Silibinin from diet or-cancer-treatment/ (accessed 6.20.22).

Wang K, Yang B, Ye H, et al. (2019). Self-strengthened oxidation-responsive lipid-polymer hybrid nanoparticles. Drug Des Devel Ther 14:823–832. https://doi.org/10.1016/j.medi.2017.10.003

Wang H, Agarwal P, Zhao G, et al. (2018). Overcoming ovarian cancer drug resistance with a cold responsive nanomaterial. ACS Cent Sci 4:567–581. https://doi.org/10.1021/acscentsci.bb00050

Wang H, Huang Y. (2020). Combination therapy based on nano codelivery for overcoming cancer drug resistance. Med. Drug Discov 6:100024. https://doi.org/10.1016/j.medic.2020.100024

Wang J. (2020). Combination treatment of cervical cancer using folate-decorated, pH-sensitive, carboplatin and paclitaxel co-loaded lipido-polymer hybrid nanoparticles. Drug Des Devel Ther 14:823–832. https://doi.org/10.2147/DDDT.S235098

Wang K, Yang B, Ye H, et al. (2019). Self-strengthened oxidation-responsive bioactivating prodrug nanosystem with sequential and synergistically facilitated drug release for treatment of breast cancer. ACS Appl Mater Interfaces 11:18914–18922. https://doi.org/10.1021/acsami.9b03056

Wang L, Wang W, Rui Z, Zhou D. (2016). The effective combination therapy of deep-seated melanoma. Lasers Surg Med 53:390–99. https://doi.org/10.1002/lsm.23292

Xu X, Lian L, Ge D-L, et al. (2018). Ratiometric delivery of two therapeutic candidates with inherently dissimilar physicochemical property through pH-sensitive core–shell nanoparticles targeting the heterogeneous tumor cells of glioma. Drug Deliv 25:1302–1318. https://doi.org/10.1080/10717544.2018.1474974

Xu H, Xie K, Zhang X-Q, et al. (2013). Enhancing tumor cell response to chemotherapy through nanoparticle-mediated delivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci USA 110:18638–43. https://doi.org/10.1073/pnas.130958110

Yang F, Li A, Liu H, Zhang H. (2018). Gastric cancer combination therapy: synthesis of a hyaluronic acid and cisplatin containing lipid prodrug coloaded with sorafenib in a nanoparticulate system to exhibit enhanced anticancer efficacy and reduced toxicity. Drug Deliv 12:3321–3333. https://doi.org/10.2147/DDDT.S176879

You S, Zhou Y, Liu L, et al. (2020). Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci 7:193–14. https://doi.org/10.3398/fmolb.2020.00193

Yasmeen MK, Khan MA, Agarwal NB, et al. (2021). Nanoformulations-based advancement in the delivery of phytopharmaceuticals for skin cancer management. J Drug Deliv Sci Technol 66:102921. https://doi.org/10.1016/j.jddst.2021.102921

Ye M, Han Y, Tang J, et al. (2017). A tumor-specific cascade amplification drug release nanoparticle for overcoming multidrug resistance in cancers. Adv Mater 29:1702342. https://doi.org/10.1002/adma.201702342

Yoon HY, Selvan ST, Yang Y, et al. (2018). Engineering nanoparticle strategies for effective cancer immunotherapy. Biomaterials 178:597–607. https://doi.org/10.1016/j.biomaterials.2018.03.036

Yoon MS, Lee YJ, Shin HJ, et al. (2020). Recent advances and challenges in controlling the spatiotemporal release of combinatorial anticancer drugs from nanoparticles. Pharmaceutics 12:1156–25. https://doi.org/10.3390/pharmaceutics12011215

Yuan YG, Gurunathan S. (2017). Combination of graphene oxide-silver nanoparticle nanocomposites and cisplatin enhances apoptosis and autophagy in human cervical cancer cells. Int J Nanomedicine 12:6537–6558. https://doi.org/10.2147/IJN.S125281

Zafar S, Akhter S, Garg N, et al. (2020). Co-encapsulation of docetaxel and thymoquinone in mPEG-DSPE-vitamin E TPGS-lipid nanocapsules for breast cancer therapy: formulation optimization and implications on cellular and in vivo toxicity. Eur J Pharm Biopharm 148:10–26. https://doi.org/10.1016/j.ejpb.2019.12.016

Zhang J, Wang L, You X, et al. (2019). Nanoparticle therapy for prostate cancer: overview and perspectives. Curr Top Med Chem 19:57–73. https://doi.org/10.2174/1568026619666190125145836

Zhang L, Zhang M, Zhou L, et al. (2018). Dual drug delivery and sequential release by amphiphilic Janus nanoparticles for liver cancer theranostics. Biomaterials 181:113–125. https://doi.org/10.1016/j.biomaterials.2018.07.060

Zhang Q, Zhang H, Ding J, et al. (2019). Corrigendum to “Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models.” J Immunol Res 2019:2070562. https://doi. org/10.1155/2019/2070562

Zhao M-D, Li J-Q, Chen F-Y, et al. (2019). Co-delivery of curcumin and paclitaxel by "Core-shell" targeting amphiphilic copolymer to reverse resistance in the treatment of ovarian cancer. Int J Nanomedicine 14:9453–9467. https://doi.org/10.2147/IJN.S124579

Zhou J, Sun M, Jin S, et al. (2019). Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells. Drug Deliv 26: 281–289. https://doi.org/10.1080/10717544.2019.1580799